Despite the success of using recombinant TRAIL ligand to trigger apoptosis in several pediatric cancers including leukemia, neuroblastoma, rhabdomyosarcoma, and Ewing’s sarcoma [52,53,54,55,56], numerous cases of TRAIL-mediated resistance have also been reported. This evidence concerns the gene TNFSF10 and rhabdomyosarcoma.